{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:49:35Z","timestamp":1789411775683,"version":"build-2803163510"},"reference-count":131,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T00:00:00Z","timestamp":1609372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["EcoSal Plus"],"published-print":{"date-parts":[[2020,12,31]]},"abstract":"<jats:p>RNA polymerases (RNAPs) accomplish the first step of gene expression in all living organisms. However, the sequence divergence between bacterial and human RNAPs makes the bacterial RNAP a promising target for antibiotic development. The most clinically important and extensively studied class of antibiotics known to inhibit bacterial RNAP are the rifamycins. For example, rifamycins are a vital element of the current combination therapy for treatment of tuberculosis. Here, we provide an overview of the history of the discovery of rifamycins, their mechanisms of action, the mechanisms of bacterial resistance against them, and progress in their further development.<\/jats:p>","DOI":"10.1128\/ecosalplus.esp-0017-2019","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T08:30:35Z","timestamp":1588062635000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":59,"title":["Inhibition of RNA Polymerase by Rifampicin and Rifamycin-Like Molecules"],"prefix":"10.1128","volume":"9","author":[{"given":"Hamed","family":"Mosaei","sequence":"first","affiliation":[{"name":"Centre for Bacterial Cell Biology, Biosciences Institute, Newcastle University, Newcastle Upon Tyne, NE2 4AX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolay","family":"Zenkin","sequence":"additional","affiliation":[{"name":"Centre for Bacterial Cell Biology, Biosciences Institute, Newcastle University, Newcastle Upon Tyne, NE2 4AX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Mosaei H Harbottle J. 2019. Mechanisms of antibiotics inhibiting bacterial RNA polymerase. Biochem Soc Trans 47:339\u2013350 http:\/\/dx.doi.org\/10.1042\/BST20180499. [PubMed]","DOI":"10.1042\/BST20180499"},{"key":"e_1_3_2_3_2","unstructured":"World Health Organization. 2018. Global Tuberculosis Report. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/274453\/9789241565646-eng.pdf?ua=1&ua=1."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Campbell EA Korzheva N Mustaev A Murakami K Nair S Goldfarb A Darst SA. 2001. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104:901\u2013912 http:\/\/dx.doi.org\/10.1016\/S0092-8674(01)00286-0.","DOI":"10.1016\/S0092-8674(01)00286-0"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","unstructured":"Floss HG Yu T-W. 2005. Rifamycin-mode of action resistance and biosynthesis. Chem Rev 105:621\u2013632 http:\/\/dx.doi.org\/10.1021\/cr030112j. [PubMed]","DOI":"10.1021\/cr030112j"},{"key":"e_1_3_2_6_2","unstructured":"Sensi P Margalith P Timbal MT. 1959. Rifomycin a new antibiotic; preliminary report. Farmaco Sci 14:146\u2013147."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Thiemann JE Zucco G Pelizza G. 1969. A proposal for the transfer of Streptomyces mediterranei Margalith and Beretta 1960 to the genus Nocardia as Nocardia mediterranea (Margalith and Beretta) comb. nov. Arch Mikrobiol 67:147\u2013155 http:\/\/dx.doi.org\/10.1007\/BF00409680. [PubMed]","DOI":"10.1007\/BF00409680"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Lechevalier MP Prauser H Labeda DP Ruan J-S. 1986. Two new genera of nocardioform actinomycetes: Amycolata gen. nov. and Amycolatopsis gen. nov. Int J Syst Bacteriol 36:29\u201337 http:\/\/dx.doi.org\/10.1099\/00207713-36-1-29.","DOI":"10.1099\/00207713-36-1-29"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Margalith P Pagani H. 1961. Rifomycin. XIV. Production of rifomycin B. Appl Microbiol 9:325\u2013334 http:\/\/dx.doi.org\/10.1128\/AEM.9.4.325-334.1961. [PubMed]","DOI":"10.1128\/am.9.4.325-334.1961"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Sensi P Timbal MT Maffii G. 1960. Rifomycin IX. Two new antibiotics of rifomycin family: rifomycin S and rifomycin SV. Preliminary report. Experientia 16:412 http:\/\/dx.doi.org\/10.1007\/BF02178838. [PubMed]","DOI":"10.1007\/BF02178838"},{"key":"e_1_3_2_11_2","unstructured":"Greco AM Ballotta R Sensi P. 1961. Activation of rifomycin B and rifomycin 0. Production and properties of rifomycin S and rifomycin S. Farmaco 16:165\u2013180."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Fueresz S Timbal MT. 1963. Antibacterial activity of rifamycins. Chemotherapia (Basel) 257:200\u2013208 http:\/\/dx.doi.org\/10.1159\/000220123. [PubMed]","DOI":"10.1159\/000220123"},{"key":"e_1_3_2_13_2","unstructured":"Bergamini N Fowst G. 1965. Rifamycin SV. A review. Arzneimittelforschung 15(Suppl):951\u20131002."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Sensi P. 1983. History of the development of rifampin. Rev Infect Dis 5(Suppl 3):S402\u2013S406 http:\/\/dx.doi.org\/10.1093\/clinids\/5.Supplement_3.S402. [PubMed]","DOI":"10.1093\/clinids\/5.Supplement_3.S402"},{"key":"e_1_3_2_15_2","unstructured":"World Health Organization. 2019. Global tuberculosis report. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/329368\/9789241565714-eng.pdf?ua=1."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","unstructured":"Hartmann G Behr W Beissner K-A Honikel K Sippel A. 1968. Antibiotics as inhibitors of nucleic acid and protein synthesis. Angew Chem Int Ed Engl 7:693\u2013701 http:\/\/dx.doi.org\/10.1002\/anie.196806931. [PubMed]","DOI":"10.1002\/anie.196806931"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"Goldstein BP. 2014. Resistance to rifampicin: a review. J Antibiot (Tokyo) 67:625\u2013630 http:\/\/dx.doi.org\/10.1038\/ja.2014.107. [PubMed]","DOI":"10.1038\/ja.2014.107"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"Calvori C Frontali L Leoni L Tecce G. 1965. Effect of rifamycin on protein synthesis. Nature 207:417\u2013418 http:\/\/dx.doi.org\/10.1038\/207417a0. [PubMed]","DOI":"10.1038\/207417a0"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Hartmann G Honikel KO Kn\u00fcsel F N\u00fcesch J. 1967. The specific inhibition of the DNA-directed RNA synthesis by rifamycin. Biochim Biophys Acta 145:843\u2013844 http:\/\/dx.doi.org\/10.1016\/0005-2787(67)90147-5.","DOI":"10.1016\/0005-2787(67)90147-5"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","unstructured":"Artsimovitch I Vassylyeva MN Svetlov D Svetlov V Perederina A Igarashi N Matsugaki N Wakatsuki S Tahirov TH Vassylyev DG. 2005. Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins. Cell 122:351\u2013363 http:\/\/dx.doi.org\/10.1016\/j.cell.2005.07.014. [PubMed]","DOI":"10.1016\/j.cell.2005.07.014"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","unstructured":"Gill SK Garcia GA. 2011. Rifamycin inhibition of WT and Rif-resistant Mycobacterium tuberculosis and Escherichia coli RNA polymerases in vitro. Tuberculosis (Edinb) 91:361\u2013369 http:\/\/dx.doi.org\/10.1016\/j.tube.2011.05.002. [PubMed]","DOI":"10.1016\/j.tube.2011.05.002"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","unstructured":"Wehrli W Kn\u00fcsel F Schmid K Staehelin M. 1968. Interaction of rifamycin with bacterial RNA polymerase. Proc Natl Acad Sci USA 61:667\u2013673 http:\/\/dx.doi.org\/10.1073\/pnas.61.2.667. [PubMed]","DOI":"10.1073\/pnas.61.2.667"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","unstructured":"Ezekiel DH Hutchins JE. 1968. Mutations affecting RNA polymerase associated with rifampicin resistance in Escherichia coli. Nature 220:276\u2013277 http:\/\/dx.doi.org\/10.1038\/220276a0. [PubMed]","DOI":"10.1038\/220276a0"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","unstructured":"Wehrli W Kn\u00fcsel F Staehelin M. 1968. Action of rifamycin on RNA-polymerase from sensitive and resistant bacteria. Biochem Biophys Res Commun 32:284\u2013288 http:\/\/dx.doi.org\/10.1016\/0006-291X(68)90382-3.","DOI":"10.1016\/0006-291X(68)90382-3"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"Sippel AE Hartmann GR. 1970. Rifampicin resistance of RNA polymerase in the binary complex with DNA. Eur J Biochem 16:152\u2013157 http:\/\/dx.doi.org\/10.1111\/j.1432-1033.1970.tb01066.x. [PubMed]","DOI":"10.1111\/j.1432-1033.1970.tb01066.x"},{"key":"e_1_3_2_26_2","unstructured":"Wehrli W Handschin J Wunderli W. 1976. Interaction between rifampicin and DNA-dependent RNA polymerase of E. coli p 397\u2013412. In Losick R Chamberlin M (ed) RNA Polymerase. Cold Spring Harbor Press Cold Spring Harbor NY."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","unstructured":"McClure WR Cech CL. 1978. On the mechanism of rifampicin inhibition of RNA synthesis. J Biol Chem 253:8949\u20138956.","DOI":"10.1016\/S0021-9258(17)34269-2"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","unstructured":"Nolte O. 1997. Rifampicin resistance in Neisseria meningitidis: evidence from a study of sibling strains description of new mutations and notes on population genetics. J Antimicrob Chemother 39:747\u2013755 http:\/\/dx.doi.org\/10.1093\/jac\/39.6.747. [PubMed]","DOI":"10.1093\/jac\/39.6.747"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","unstructured":"Ramaswamy S Musser JM. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 79:3\u201329 http:\/\/dx.doi.org\/10.1054\/tuld.1998.0002. [PubMed]","DOI":"10.1054\/tuld.1998.0002"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","unstructured":"Zhang Y Yew W-W. 2015. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. Int J Tuberc Lung Dis 19:1276\u20131289 http:\/\/dx.doi.org\/10.5588\/ijtld.15.0389. [PubMed]","DOI":"10.5588\/ijtld.15.0389"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","unstructured":"Morse R O\u2019Hanlon K Virji M Collins MD. 1999. Isolation of rifampin-resistant mutants of Listeria monocytogenes and their characterization by rpoB gene sequencing temperature sensitivity for growth and interaction with an epithelial cell line. J Clin Microbiol 37:2913\u20132919 http:\/\/dx.doi.org\/10.1128\/JCM.37.9.2913-2919.1999. [PubMed]","DOI":"10.1128\/JCM.37.9.2913-2919.1999"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","unstructured":"Mustaev A Zaychikov E Severinov K Kashlev M Polyakov A Nikiforov V Goldfarb A. 1994. Topology of the RNA polymerase active center probed by chimeric rifampicin-nucleotide compounds. Proc Natl Acad Sci USA 91:12036\u201312040 http:\/\/dx.doi.org\/10.1073\/pnas.91.25.12036. [PubMed]","DOI":"10.1073\/pnas.91.25.12036"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","unstructured":"Severinov K Mustaev A Severinova E Kozlov M Darst SA Goldfarb A. 1995. The beta subunit Rif-cluster I is only angstroms away from the active center of Escherichia coli RNA polymerase. J Biol Chem 270:29428\u201329432 http:\/\/dx.doi.org\/10.1074\/jbc.270.49.29428. [PubMed]","DOI":"10.1074\/jbc.270.49.29428"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","unstructured":"Williams DL Spring L Collins L Miller LP Heifets LB Gangadharam PR Gillis TP. 1998. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 42:1853\u20131857 http:\/\/dx.doi.org\/10.1128\/AAC.42.7.1853. [PubMed]","DOI":"10.1128\/AAC.42.7.1853"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","unstructured":"Artsimovitch I Vassylyev DG. 2006. Is it easy to stop RNA polymerase? Cell Cycle 5:399\u2013404 http:\/\/dx.doi.org\/10.4161\/cc.5.4.2466. [PubMed]","DOI":"10.4161\/cc.5.4.2466"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","unstructured":"Feklistov A Mekler V Jiang Q Westblade LF Irschik H Jansen R Mustaev A Darst SA Ebright RH. 2008. Rifamycins do not function by allosteric modulation of binding of Mg2+ to the RNA polymerase active center. Proc Natl Acad Sci USA 105:14820\u201314825 http:\/\/dx.doi.org\/10.1073\/pnas.0802822105. [PubMed]","DOI":"10.1073\/pnas.0802822105"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","unstructured":"Molodtsov V Nawarathne IN Scharf NT Kirchhoff PD Showalter HD Garcia GA Murakami KS. 2013. X-ray crystal structures of the Escherichia coli RNA polymerase in complex with benzoxazinorifamycins. J Med Chem 56:4758\u20134763 http:\/\/dx.doi.org\/10.1021\/jm4004889. [PubMed]","DOI":"10.1021\/jm4004889"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","unstructured":"Zenkin N Severinov K. 2004. The role of RNA polymerase \u03c3 subunit in promoter-independent initiation of transcription. Proc Natl Acad Sci USA 101:4396\u20134400 http:\/\/dx.doi.org\/10.1073\/pnas.0400886101.","DOI":"10.1073\/pnas.0400886101"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","unstructured":"Bochkareva A Zenkin N. 2013. The \u03c370 region 1.2 regulates promoter escape by unwinding DNA downstream of the transcription start site. Nucleic Acids Res 41:4565\u20134572 http:\/\/dx.doi.org\/10.1093\/nar\/gkt116. [PubMed]","DOI":"10.1093\/nar\/gkt116"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","unstructured":"Pupov D Kuzin I Bass I Kulbachinskiy A. 2014. Distinct functions of the RNA polymerase \u03c3 subunit region 3.2 in RNA priming and promoter escape. Nucleic Acids Res 42:4494\u20134504 http:\/\/dx.doi.org\/10.1093\/nar\/gkt1384. [PubMed]","DOI":"10.1093\/nar\/gkt1384"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","unstructured":"Lin W Mandal S Degen D Liu Y Ebright YW Li S Feng Y Zhang Y Mandal S Jiang Y Liu S Gigliotti M Talaue M Connell N Das K Arnold E Ebright RH. 2017. Structural basis of Mycobacterium tuberculosis transcription and transcription inhibition. Mol Cell 66:169\u2013179.e8 http:\/\/dx.doi.org\/10.1016\/j.molcel.2017.03.001. [PubMed]","DOI":"10.1016\/j.molcel.2017.03.001"},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","unstructured":"Mosaei H Molodtsov V Kepplinger B Harbottle J Moon CWCW Jeeves RERE Ceccaroni L Shin Y Morton-Laing S Marrs ECL Wills C Clegg W Yuzenkova Y Perry JDJD Bacon J Errington J Allenby NEE Hall MJMJ Murakami KSKS Zenkin N. 2018. Mode of Action of kanglemycin A an ansamycin natural product that is active against rifampicin-resistant Mycobacterium tuberculosis. Mol Cell 72:263\u2013274.e5 http:\/\/dx.doi.org\/10.1016\/j.molcel.2018.08.028. [PubMed]","DOI":"10.1016\/j.molcel.2018.08.028"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","unstructured":"Peek J Lilic M Montiel D Milshteyn A Woodworth I Biggins JB Ternei MA Calle PY Danziger M Warrier T Saito K Braffman N Fay A Glickman MS Darst SA Campbell EA Brady SF. 2018. Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanism. Nat Commun 9:4147 http:\/\/dx.doi.org\/10.1038\/s41467-018-06587-2. [PubMed]","DOI":"10.1038\/s41467-018-06587-2"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","unstructured":"Zenkin N Kulbachinskiy A Bass I Nikiforov V. 2005. Different rifampin sensitivities of Escherichia coli and Mycobacterium tuberculosis RNA polymerases are not explained by the difference in the \u03b2-subunit rifampin regions I and II. Antimicrob Agents Chemother 49:1587\u20131590 http:\/\/dx.doi.org\/10.1128\/AAC.49.4.1587-1590.2005. [PubMed]","DOI":"10.1128\/AAC.49.4.1587-1590.2005"},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","unstructured":"Harshey RM Ramakrishnan T. 1976. Purification and properties of DNA-dependent RNA polymerase from Mycobacterium tuberculosis H37RV. Biochim Biophys Acta 432:49\u201359 http:\/\/dx.doi.org\/10.1016\/0005-2787(76)90040-X.","DOI":"10.1016\/0005-2787(76)90040-X"},{"key":"e_1_3_2_46_2","doi-asserted-by":"crossref","unstructured":"Fujii K Saito H Tomioka H Mae T Hosoe K. 1995. Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648. Antimicrob Agents Chemother 39:1489\u20131492 http:\/\/dx.doi.org\/10.1128\/AAC.39.7.1489. [PubMed]","DOI":"10.1128\/AAC.39.7.1489"},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","unstructured":"F\u00e1bry M S\u00fcmegi J Venetianer P. 1976. Purification and properties of the RNA polymerase of an extremely thermophilic bacterium: Thermus aquaticus T2. Biochim Biophys Acta 435:228\u2013235 http:\/\/dx.doi.org\/10.1016\/0005-2787(76)90104-0.","DOI":"10.1016\/0005-2787(76)90104-0"},{"key":"e_1_3_2_48_2","doi-asserted-by":"crossref","unstructured":"Minakhin L Nechaev S Campbell EA Severinov K. 2001. Recombinant Thermus aquaticus RNA polymerase a new tool for structure-based analysis of transcription. J Bacteriol 183:71\u201376 http:\/\/dx.doi.org\/10.1128\/JB.183.1.71-76.2001. [PubMed]","DOI":"10.1128\/JB.183.1.71-76.2001"},{"key":"e_1_3_2_49_2","doi-asserted-by":"crossref","unstructured":"Molodtsov V Scharf NT Stefan MA Garcia GA Murakami KS. 2017. Structural basis for rifamycin resistance of bacterial RNA polymerase by the three most clinically important RpoB mutations found in Mycobacterium tuberculosis. Mol Microbiol 103:1034\u20131045 http:\/\/dx.doi.org\/10.1111\/mmi.13606. [PubMed]","DOI":"10.1111\/mmi.13606"},{"key":"e_1_3_2_50_2","doi-asserted-by":"crossref","unstructured":"Wehrli W Staehelin M. 1969. The rifamycins: relation of chemical structure and action on RNA polymerase. Biochim Biophys Acta 182:24\u201329 http:\/\/dx.doi.org\/10.1016\/0005-2787(69)90516-4.","DOI":"10.1016\/0005-2787(69)90516-4"},{"key":"e_1_3_2_51_2","doi-asserted-by":"crossref","unstructured":"Wehrli W. 1977. Ansamycins. Chemistry biosynthesis and biological activity. Top Curr Chem 72:21\u201349 http:\/\/dx.doi.org\/10.1007\/BFb0048448. [PubMed]","DOI":"10.1007\/BFb0048448"},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","unstructured":"Rastogi N Goh KS Berchel M Bryskier A. 2000. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis Mycobacterium africanum Mycobacterium bovis and M. bovis BCG. J Antimicrob Chemother 46:565\u2013570 http:\/\/dx.doi.org\/10.1093\/jac\/46.4.565. [PubMed]","DOI":"10.1093\/jac\/46.4.565"},{"key":"e_1_3_2_53_2","doi-asserted-by":"crossref","unstructured":"Nigam A Almabruk KH Saxena A Yang J Mukherjee U Kaur H Kohli P Kumari R Singh P Zakharov LN Singh Y Mahmud T Lal R. 2014. Modification of rifamycin polyketide backbone leads to improved drug activity against rifampicin-resistant Mycobacterium tuberculosis. J Biol Chem 289:21142\u201321152 http:\/\/dx.doi.org\/10.1074\/jbc.M114.572636. [PubMed]","DOI":"10.1074\/jbc.M114.572636"},{"key":"e_1_3_2_54_2","doi-asserted-by":"crossref","unstructured":"Wilhelm JM Oleinick NL Corcoran JW. 1968. The inhibition of bacterial RNA synthesis by the rifamycin antibiotics. Biochim Biophys Acta 166:268\u2013271 http:\/\/dx.doi.org\/10.1016\/0005-2787(68)90515-7.","DOI":"10.1016\/0005-2787(68)90515-7"},{"key":"e_1_3_2_55_2","doi-asserted-by":"crossref","unstructured":"Maggi N Furesz S Sensi P. 1968. Rifomycins. XLIX. Influence of the carboxyl group on the antibacterial activity of rifomycins. J Med Chem 11:368\u2013369 http:\/\/dx.doi.org\/10.1021\/jm00308a042. [PubMed]","DOI":"10.1021\/jm00308a042"},{"key":"e_1_3_2_56_2","doi-asserted-by":"crossref","unstructured":"Sensi P Maggi N Ballotta R Fueresz S Pallanza R Arioli V. 1964. Rifamycins. XXXV. Amides and hydrazides of rifamycin B. J Med Chem 7:596\u2013602 http:\/\/dx.doi.org\/10.1021\/jm00335a005. [PubMed]","DOI":"10.1021\/jm00335a005"},{"key":"e_1_3_2_57_2","unstructured":"Pallanza R F\u00fcr\u00e9sz S Timbal MT Carniti G. 1965. In vitro bacteriological studies on rifamycin B diethylamide (rifamide). Arzneimittelforschung 15:800\u2013802."},{"key":"e_1_3_2_58_2","doi-asserted-by":"crossref","unstructured":"Stanzani L Venturini AP Mantovani V. 1978. A new tolypomycin-Y derivative: in vitro and in vivo antimicrobial activity. J Antibiot (Tokyo) 31:1195\u20131200 http:\/\/dx.doi.org\/10.7164\/antibiotics.31.1195. [PubMed]","DOI":"10.7164\/antibiotics.31.1195"},{"key":"e_1_3_2_59_2","unstructured":"Brufani M Cellai L Cerrini S Fedeli W Segre A Vaciago A. 1982. Structure-activity relationships in the ansamycins. Molecular structure and activity of 3-carbomethoxy rifamycin S. Mol Pharmacol 21:394\u2013399."},{"key":"e_1_3_2_60_2","doi-asserted-by":"crossref","unstructured":"Bellomo P Marchi E Mascellani G Brufani M. 1981. Synthesis and antibacterial activity of some ester amides and hydrazides of 3-carboxyrifamycin S. Relationship between structure and activity of ansamycins. J Med Chem 24:1310\u20131314 http:\/\/dx.doi.org\/10.1021\/jm00143a010. [PubMed]","DOI":"10.1021\/jm00143a010"},{"key":"e_1_3_2_61_2","doi-asserted-by":"crossref","unstructured":"Dampier MF Whitlock HW Jr. 1975. Letter: electronegative groups at C-3 of rifamycin S enhance its activity toward DNA-dependent RNA polymerase. J Am Chem Soc 97:6254\u20136256 http:\/\/dx.doi.org\/10.1021\/ja00854a057. [PubMed]","DOI":"10.1021\/ja00854a057"},{"key":"e_1_3_2_62_2","unstructured":"Arora SK. 1983. Correlation of structure and activity in ansamycins. Molecular structure of sodium rifamycin SV. Mol Pharmacol 23:133\u2013140."},{"key":"e_1_3_2_63_2","doi-asserted-by":"crossref","unstructured":"Bartolucci C Cellai L Di Filippo P Lamba D Segre AL Bianco AD Guiso M Pasquali V Brufani M. 2018. Hydrogenation of the ansa-chain of rifamycins. X-ray crystal structure of (16S)-16 17 18 19-tetrahydrorifamycin S. Helv Chim Acta 76:1459\u20131468 http:\/\/dx.doi.org\/10.1002\/hlca.19930760406.","DOI":"10.1002\/hlca.19930760406"},{"key":"e_1_3_2_64_2","doi-asserted-by":"crossref","unstructured":"Brufani M Cerrini S Fedeli W Vaciago A. 1974. Rifamycins: an insight into biological activity based on structural investigations. J Mol Biol 87:409\u2013435 http:\/\/dx.doi.org\/10.1016\/0022-2836(74)90094-1.","DOI":"10.1016\/0022-2836(74)90094-1"},{"key":"e_1_3_2_65_2","doi-asserted-by":"crossref","unstructured":"Bacchi A Pelizzi G. 1999. Conformational variety for the ansa chain of rifamycins: comparison of observed crystal structures and molecular dynamics simulations. J Comput Aided Mol Des 13:385\u2013396 http:\/\/dx.doi.org\/10.1023\/A:1008070316079. [PubMed]","DOI":"10.1023\/A:1008070316079"},{"key":"e_1_3_2_66_2","doi-asserted-by":"crossref","unstructured":"Bacchi A Pelizzi G Nebuloni M Ferrari P. 1998. Comprehensive study on structure-activity relationships of rifamycins: discussion of molecular and crystal structure and spectroscopic and thermochemical properties of rifamycin O. J Med Chem 41:2319\u20132332 http:\/\/dx.doi.org\/10.1021\/jm970791o. [PubMed]","DOI":"10.1021\/jm970791o"},{"key":"e_1_3_2_67_2","doi-asserted-by":"crossref","unstructured":"Aristoff PA Garcia GA Kirchhoff PD Showalter HD. 2010. Rifamycins: obstacles and opportunities. Tuberculosis (Edinb) 90:94\u2013118 http:\/\/dx.doi.org\/10.1016\/j.tube.2010.02.001. [PubMed]","DOI":"10.1016\/j.tube.2010.02.001"},{"key":"e_1_3_2_68_2","doi-asserted-by":"crossref","unstructured":"Temple ME Nahata MC. 1999. Rifapentine: its role in the treatment of tuberculosis. Ann Pharmacother 33:1203\u20131210 http:\/\/dx.doi.org\/10.1345\/aph.18450. [PubMed]","DOI":"10.1345\/aph.18450"},{"key":"e_1_3_2_69_2","doi-asserted-by":"crossref","unstructured":"Arioli V Berti M Carniti G Randisi E Rossi E Scotti R. 1981. Antibacterial activity of DL 473 a new semisynthetic rifamycin derivative. J Antibiot (Tokyo) 34:1026\u20131032 http:\/\/dx.doi.org\/10.7164\/antibiotics.34.1026. [PubMed]","DOI":"10.7164\/antibiotics.34.1026"},{"key":"e_1_3_2_70_2","doi-asserted-by":"crossref","unstructured":"Bemer-Melchior P Bryskier A Drugeon HB. 2000. Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex. J Antimicrob Chemother 46:571\u2013576 http:\/\/dx.doi.org\/10.1093\/jac\/46.4.571. [PubMed]","DOI":"10.1093\/jac\/46.4.571"},{"key":"e_1_3_2_71_2","doi-asserted-by":"crossref","unstructured":"Knoll BM Nog R Wu Y Dhand A. 2017. Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates. Infection 45:335\u2013339 http:\/\/dx.doi.org\/10.1007\/s15010-017-1004-5. [PubMed]","DOI":"10.1007\/s15010-017-1004-5"},{"key":"e_1_3_2_72_2","unstructured":"Maggi N Pallanza R Sensi P. 1965. New derivatives of rifamycin SV. Antimicrob Agents Chemother 5:765\u2013769."},{"key":"e_1_3_2_73_2","unstructured":"Kradolfer F Neipp L Sackmann W. 1966. Chemotherapeutic activity of new derivatives of rifamycin. Antimicrob Agents Chemother 6:359\u2013364."},{"key":"e_1_3_2_74_2","doi-asserted-by":"crossref","unstructured":"Villain-Guillot P Gualtieri M Bastide L Leonetti J-P. 2007. In vitro activities of different inhibitors of bacterial transcription against Staphylococcus epidermidis biofilm. Antimicrob Agents Chemother 51:3117\u20133121 http:\/\/dx.doi.org\/10.1128\/AAC.00343-07. [PubMed]","DOI":"10.1128\/AAC.00343-07"},{"key":"e_1_3_2_75_2","unstructured":"Cellai L Cerrini S Segre A Battistoni C Cossu G Mattogno G Brufani M Marchi E. 1985. A study of structure-activity relationships in 4-deoxypyrido[1\u2032 2\u2032-1 2]imidazo[5 4-c]rifamycin SV derivatives by electron spectroscopy for chemical analysis and 1H NMR. Mol Pharmacol 27:103\u2013108."},{"key":"e_1_3_2_76_2","doi-asserted-by":"crossref","unstructured":"Adachi JA DuPont HL. 2006. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 42:541\u2013547 http:\/\/dx.doi.org\/10.1086\/499950. [PubMed]","DOI":"10.1086\/499950"},{"key":"e_1_3_2_77_2","doi-asserted-by":"crossref","unstructured":"Ruiz J Mensa L Pons MJ Vila J Gascon J. 2008. Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability. J Antimicrob Chemother 61:1016\u20131019 http:\/\/dx.doi.org\/10.1093\/jac\/dkn078. [PubMed]","DOI":"10.1093\/jac\/dkn078"},{"key":"e_1_3_2_78_2","doi-asserted-by":"crossref","unstructured":"Kothary V Scherl EJ Bosworth B Jiang Z-D Dupont HL Harel J Simpson KW Dogan B. 2013. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use mutations in rpoB and activity of Phe-Arg-\u03b2-naphthylamide-inhibitable efflux pumps. Antimicrob Agents Chemother 57:811\u2013817 http:\/\/dx.doi.org\/10.1128\/AAC.02163-12. [PubMed]","DOI":"10.1128\/AAC.02163-12"},{"key":"e_1_3_2_79_2","doi-asserted-by":"crossref","unstructured":"Sanfilippo A Della Bruna C Marsili L Morvillo E Pasqualucci CR Schioppacassi G Ungheri D. 1980. Biological activity of a new class of rifamycins. Spiro-piperidyl-rifamycins. J Antibiot (Tokyo) 33:1193\u20131198 http:\/\/dx.doi.org\/10.7164\/antibiotics.33.1193. [PubMed]","DOI":"10.7164\/antibiotics.33.1193"},{"key":"e_1_3_2_80_2","doi-asserted-by":"crossref","unstructured":"Yang B Koga H Ohno H Ogawa K Fukuda M Hirakata Y Maesaki S Tomono K Tashiro T Kohno S. 1998. Relationship between antimycobacterial activities of rifampicin rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother 42:621\u2013628 http:\/\/dx.doi.org\/10.1093\/jac\/42.5.621. [PubMed]","DOI":"10.1093\/jac\/42.5.621"},{"key":"e_1_3_2_81_2","doi-asserted-by":"crossref","unstructured":"Berrada ZL Lin S-YG Rodwell TC Nguyen D Schecter GF Pham L Janda JM Elmaraachli W Catanzaro A Desmond E. 2016. Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex. Diagn Microbiol Infect Dis 85:177\u2013181 http:\/\/dx.doi.org\/10.1016\/j.diagmicrobio.2016.01.019. [PubMed]","DOI":"10.1016\/j.diagmicrobio.2016.01.019"},{"key":"e_1_3_2_82_2","doi-asserted-by":"crossref","unstructured":"Whitfield MG Warren RM Mathys V Scott L De Vos E Stevens W Streicher EM Groenen G Sirgel FA Van Rie A. 2018. The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis. J Antimicrob Chemother 73:2667\u20132674 http:\/\/dx.doi.org\/10.1093\/jac\/dky248. [PubMed]","DOI":"10.1093\/jac\/dky248"},{"key":"e_1_3_2_83_2","unstructured":"Ungheri D Della Bruna C Sanfilippo A. 1984. Studies on the mechanism of action of the spiropiperidylrifamycin LM 427 on rifampicin-resistant M. tuberculosis. Drugs Exp Clin Res 10:681\u2013689."},{"key":"e_1_3_2_84_2","doi-asserted-by":"crossref","unstructured":"Baciewicz AM Chrisman CR Finch CK Self TH. 2008. Update on rifampin and rifabutin drug interactions. Am J Med Sci 335:126\u2013136 http:\/\/dx.doi.org\/10.1097\/MAJ.0b013e31814a586a. [PubMed]","DOI":"10.1097\/MAJ.0b013e31814a586a"},{"key":"e_1_3_2_85_2","doi-asserted-by":"crossref","unstructured":"Barluenga J Aznar F Garc\u00eda A-B Cabal M-P Palacios JJ Men\u00e9ndez M-A. 2006. New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis. Bioorg Med Chem Lett 16:5717\u20135722 http:\/\/dx.doi.org\/10.1016\/j.bmcl.2006.08.090. [PubMed]","DOI":"10.1016\/j.bmcl.2006.08.090"},{"key":"e_1_3_2_86_2","doi-asserted-by":"crossref","unstructured":"Garc\u00eda A-B Palacios JJ Ruiz M-J Barluenga J Aznar F Cabal M-P Garc\u00eda JM D\u00edaz N. 2010. Strong in vitro activities of two new rifabutin analogs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 54:5363\u20135365 http:\/\/dx.doi.org\/10.1128\/AAC.00149-10. [PubMed]","DOI":"10.1128\/AAC.00149-10"},{"key":"e_1_3_2_87_2","doi-asserted-by":"crossref","unstructured":"Yamane T Hashizume T Yamashita K Konishi E Hosoe K Hidaka T Watanabe K Kawaharada H Yamamoto T Kuze F. 1993. Synthesis and biological activity of 3\u2032-hydroxy-5\u2032-aminobenzoxazinorifamycin derivatives. Chem Pharm Bull (Tokyo) 41:148\u2013155 http:\/\/dx.doi.org\/10.1248\/cpb.41.148. [PubMed]","DOI":"10.1248\/cpb.41.148"},{"key":"e_1_3_2_88_2","doi-asserted-by":"crossref","unstructured":"Fujii K Tsuji A Miyazaki S Yamaguchi K Goto S. 1994. In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657 new rifamycin derivatives. Antimicrob Agents Chemother 38:1118\u20131122 http:\/\/dx.doi.org\/10.1128\/AAC.38.5.1118. [PubMed]","DOI":"10.1128\/AAC.38.5.1118"},{"key":"e_1_3_2_89_2","doi-asserted-by":"crossref","unstructured":"Luna-Herrera J Reddy MV Gangadharam PR. 1995. In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli. Antimicrob Agents Chemother 39:440\u2013444 http:\/\/dx.doi.org\/10.1128\/AAC.39.2.440. [PubMed]","DOI":"10.1128\/AAC.39.2.440"},{"key":"e_1_3_2_90_2","doi-asserted-by":"crossref","unstructured":"Moghazeh SL Pan X Arain T Stover CK Musser JM Kreiswirth BN. 1996. Comparative antimycobacterial activities of rifampin rifapentine and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother 40:2655\u20132657 http:\/\/dx.doi.org\/10.1128\/AAC.40.11.2655. [PubMed]","DOI":"10.1128\/AAC.40.11.2655"},{"key":"e_1_3_2_91_2","doi-asserted-by":"crossref","unstructured":"Rothstein DM Suchland RJ Xia M Murphy CK Stamm WE Murphy CK Stamm WE. 2008. Rifalazil retains activity against rifampin-resistant mutants of Chlamydia pneumoniae. J Antibiot (Tokyo) 61:489\u2013495 http:\/\/dx.doi.org\/10.1038\/ja.2008.65. [PubMed]","DOI":"10.1038\/ja.2008.65"},{"key":"e_1_3_2_92_2","doi-asserted-by":"crossref","unstructured":"Lounis N Roscigno G. 2004. In vitro and in vivo activities of new rifamycin derivatives against mycobacterial infections. Curr Pharm Des 10:3229\u20133238 http:\/\/dx.doi.org\/10.2174\/1381612043383287. [PubMed]","DOI":"10.2174\/1381612043383287"},{"key":"e_1_3_2_93_2","doi-asserted-by":"crossref","unstructured":"Global Alliance for TB Drug Development (TB Alliance). 2008. Rifalazil. Tuberculosis (Edinb) 88:148\u2013150 http:\/\/dx.doi.org\/10.1016\/S1472-9792(08)70023-4.","DOI":"10.1016\/S1472-9792(08)70023-4"},{"key":"e_1_3_2_94_2","doi-asserted-by":"crossref","unstructured":"Mae T Hosoe K Yamamoto T Hidaka T Ohashi T Kleeman JM Adams PE. 1998. Effect of a new rifamycin derivative rifalazil on liver microsomal enzyme induction in rat and dog. Xenobiotica 28:759\u2013766 http:\/\/dx.doi.org\/10.1080\/004982598239173. [PubMed]","DOI":"10.1080\/004982598239173"},{"key":"e_1_3_2_95_2","doi-asserted-by":"crossref","unstructured":"Gill SK Xu H Kirchhoff PD Cierpicki T Turbiak AJ Wan B Zhang N Peng K-W Franzblau SG Garcia GA Showalter HDH. 2012. Structure-based design of novel benzoxazinorifamycins with potent binding affinity to wild-type and rifampin-resistant mutant Mycobacterium tuberculosis RNA polymerases. J Med Chem 55:3814\u20133826 http:\/\/dx.doi.org\/10.1021\/jm201716n. [PubMed]","DOI":"10.1021\/jm201716n"},{"key":"e_1_3_2_96_2","doi-asserted-by":"crossref","unstructured":"Sensi P Ballotta R Greco AM Gallo GG. 1961. Rifomycin. XV. Activation of rifomycin B and Rifomycin O. Production and properties of rifomycin S and rifomycin SV. Farm Ed Sci 16:165\u2013180.","DOI":"10.1007\/BF02178838"},{"key":"e_1_3_2_97_2","doi-asserted-by":"crossref","unstructured":"Malmborg A-S Molin L Nystr\u00f6m B. 1971. Rifampicin compared with penicillin in the treatment of gonorrhea. Chemotherapy 16:319\u2013325 http:\/\/dx.doi.org\/10.1159\/000220742. [PubMed]","DOI":"10.1159\/000220742"},{"key":"e_1_3_2_98_2","doi-asserted-by":"crossref","unstructured":"DeBoer C Meulman PA Wnuk RJ Peterson DH. 1970. Geldanamycin a new antibiotic. J Antibiot (Tokyo) 23:442\u2013447 http:\/\/dx.doi.org\/10.7164\/antibiotics.23.442. [PubMed]","DOI":"10.7164\/antibiotics.23.442"},{"key":"e_1_3_2_99_2","doi-asserted-by":"crossref","unstructured":"Telenti A Imboden P Marchesi F Lowrie D Cole S Colston MJ Matter L Schopfer K Bodmer T. 1993. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341:647\u2013650 http:\/\/dx.doi.org\/10.1016\/0140-6736(93)90417-F.","DOI":"10.1016\/0140-6736(93)90417-F"},{"key":"e_1_3_2_100_2","doi-asserted-by":"crossref","unstructured":"Heil A Zillig W. 1970. Reconstitution of bacterial DNA-dependent RNA-polymerase from isolated subunits as a tool for the elucidation of the role of the subunits in transcription. FEBS Lett 11:165\u2013168 http:\/\/dx.doi.org\/10.1016\/0014-5793(70)80519-1.","DOI":"10.1016\/0014-5793(70)80519-1"},{"key":"e_1_3_2_101_2","doi-asserted-by":"crossref","unstructured":"Heep M Rieger U Beck D Lehn N. 2000. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob Agents Chemother 44:1075\u20131077 http:\/\/dx.doi.org\/10.1128\/AAC.44.4.1075-1077.2000. [PubMed]","DOI":"10.1128\/AAC.44.4.1075-1077.2000"},{"key":"e_1_3_2_102_2","doi-asserted-by":"crossref","unstructured":"Heep M Beck D Bayerd\u00f6rffer E Lehn N. 1999. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 43:1497\u20131499 http:\/\/dx.doi.org\/10.1128\/AAC.43.6.1497. [PubMed]","DOI":"10.1128\/AAC.43.6.1497"},{"key":"e_1_3_2_103_2","doi-asserted-by":"crossref","unstructured":"Cai X-C Xi H Liang L Liu J-D Liu C-H Xue Y-R Yu X-Y. 2017. Rifampicin-resistance mutations in the rpoB gene in Bacillus velezensis CC09 have pleiotropic effects. Front Microbiol 8:178 http:\/\/dx.doi.org\/10.3389\/fmicb.2017.00178.","DOI":"10.3389\/fmicb.2017.00178"},{"key":"e_1_3_2_104_2","doi-asserted-by":"crossref","unstructured":"Severinov K Soushko M Goldfarb A Nikiforov V. 1994. RifR mutations in the beginning of the Escherichia coli rpoB gene. Mol Gen Genet 244:120\u2013126 http:\/\/dx.doi.org\/10.1007\/BF00283512. [PubMed]","DOI":"10.1007\/BF00283512"},{"key":"e_1_3_2_105_2","doi-asserted-by":"crossref","unstructured":"Severinov K Soushko M Goldfarb A Nikiforov V. 1993. Rifampicin region revisited. New rifampicin-resistant and streptolydigin-resistant mutants in the beta subunit of Escherichia coli RNA polymerase. J Biol Chem 268:14820\u201314825.","DOI":"10.1016\/S0021-9258(18)82407-3"},{"key":"e_1_3_2_106_2","doi-asserted-by":"crossref","unstructured":"Sandgren A Strong M Muthukrishnan P Weiner BK Church GM Murray MB. 2009. Tuberculosis drug resistance mutation database. PLoS Med 6:e2 http:\/\/dx.doi.org\/10.1371\/journal.pmed.1000002. [PubMed]","DOI":"10.1371\/journal.pmed.1000002"},{"key":"e_1_3_2_107_2","doi-asserted-by":"crossref","unstructured":"Sutherland C Murakami KS. 2018. An introduction to the structure and function of the catalytic core enzyme of Escherichia coli RNA polymerase. Ecosal Plus 2018 http:\/\/dx.doi.org\/10.1128\/ecosalplus.ESP-0004-2018.","DOI":"10.1128\/ecosalplus.ESP-0004-2018"},{"key":"e_1_3_2_108_2","doi-asserted-by":"crossref","unstructured":"Maffioli SI Zhang Y Degen D Carzaniga T Del Gatto G Serina S Monciardini P Mazzetti C Guglierame P Candiani G Chiriac AI Facchetti G Kaltofen P Sahl H-G Deh\u00f2 G Donadio S Ebright RH. 2017. Antibacterial nucleoside-analog inhibitor of bacterial RNA polymerase. Cell 169:1240\u20131248.e23 http:\/\/dx.doi.org\/10.1016\/j.cell.2017.05.042. [PubMed]","DOI":"10.1016\/j.cell.2017.05.042"},{"key":"e_1_3_2_109_2","doi-asserted-by":"crossref","unstructured":"Song T Park Y Shamputa IC Seo S Lee SY Jeon H-S Choi H Lee M Glynne RJ Barnes SW Walker JR Batalov S Yusim K Feng S Tung C-S Theiler J Via LE Boshoff HIM Murakami KS Korber B Barry CE III Cho S-N. 2014. Fitness costs of rifampicin resistance in Mycobacterium tuberculosis are amplified under conditions of nutrient starvation and compensated by mutation in the \u03b2\u2032 subunit of RNA polymerase. Mol Microbiol 91:1106\u20131119 http:\/\/dx.doi.org\/10.1111\/mmi.12520. [PubMed]","DOI":"10.1111\/mmi.12520"},{"key":"e_1_3_2_110_2","doi-asserted-by":"crossref","unstructured":"Kim H Kim S-H Ying Y-H Kim H-JH Koh Y-H Kim C-J Lee S-H Cha C-Y Kook Y-H Kim B-J. 2005. Mechanism of natural rifampin resistance of Streptomyces spp. Syst Appl Microbiol 28:398\u2013404 http:\/\/dx.doi.org\/10.1016\/j.syapm.2005.02.009. [PubMed]","DOI":"10.1016\/j.syapm.2005.02.009"},{"key":"e_1_3_2_111_2","doi-asserted-by":"crossref","unstructured":"Piddock LJV Williams KJ Ricci V. 2000. Accumulation of rifampicin by Mycobacterium aurum Mycobacterium smegmatis and Mycobacterium tuberculosis. J Antimicrob Chemother 45:159\u2013165 http:\/\/dx.doi.org\/10.1093\/jac\/45.2.159. [PubMed]","DOI":"10.1093\/jac\/45.2.159"},{"key":"e_1_3_2_112_2","doi-asserted-by":"crossref","unstructured":"Li G Zhang J Guo Q Wei J Jiang Y Zhao X Zhao LL Liu Z Lu J Wan K. 2015. Study of efflux pump gene expression in rifampicin-monoresistant Mycobacterium tuberculosis clinical isolates. J Antibiot (Tokyo) 68:431\u2013435 http:\/\/dx.doi.org\/10.1038\/ja.2015.9. [PubMed]","DOI":"10.1038\/ja.2015.9"},{"key":"e_1_3_2_113_2","doi-asserted-by":"crossref","unstructured":"Hoshino Y Fujii S Shinonaga H Arai K Saito F Fukai T Satoh H Miyazaki Y Ishikawa J. 2010. Monooxygenation of rifampicin catalyzed by the rox gene product of Nocardia farcinica: structure elucidation gene identification and role in drug resistance. J Antibiot (Tokyo) 63:23\u201328 http:\/\/dx.doi.org\/10.1038\/ja.2009.116. [PubMed]","DOI":"10.1038\/ja.2009.116"},{"key":"e_1_3_2_114_2","doi-asserted-by":"crossref","unstructured":"Rominski A Roditscheff A Selchow P B\u00f6ttger EC Sander P. 2017. Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591. J Antimicrob Chemother 72:376\u2013384 http:\/\/dx.doi.org\/10.1093\/jac\/dkw466. [PubMed]","DOI":"10.1093\/jac\/dkw466"},{"key":"e_1_3_2_115_2","doi-asserted-by":"crossref","unstructured":"Combrink KD Denton DA Harran S Ma Z Chapo K Yan D Bonventre E Roche ED Doyle TB Robertson GT Lynch AS. 2007. New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases. Bioorg Med Chem Lett 17:522\u2013526 http:\/\/dx.doi.org\/10.1016\/j.bmcl.2006.10.016. [PubMed]","DOI":"10.1016\/j.bmcl.2006.10.016"},{"key":"e_1_3_2_116_2","doi-asserted-by":"crossref","unstructured":"Andersson DI Levin BR. 1999. The biological cost of antibiotic resistance. Curr Opin Microbiol 2:489\u2013493 http:\/\/dx.doi.org\/10.1016\/S1369-5274(99)00005-3.","DOI":"10.1016\/S1369-5274(99)00005-3"},{"key":"e_1_3_2_117_2","doi-asserted-by":"crossref","unstructured":"Andersson DI Hughes D. 2010. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 8:260\u2013271 http:\/\/dx.doi.org\/10.1038\/nrmicro2319. [PubMed]","DOI":"10.1038\/nrmicro2319"},{"key":"e_1_3_2_118_2","doi-asserted-by":"crossref","unstructured":"Mariam DH Mengistu Y Hoffner SE Andersson DI. 2004. Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob Agents Chemother 48:1289\u20131294 http:\/\/dx.doi.org\/10.1128\/AAC.48.4.1289-1294.2004. [PubMed]","DOI":"10.1128\/AAC.48.4.1289-1294.2004"},{"key":"e_1_3_2_119_2","doi-asserted-by":"crossref","unstructured":"Gagneux S Long CD Small PM Van T Schoolnik GK Bohannan BJM. 2006. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312:1944\u20131946 http:\/\/dx.doi.org\/10.1126\/science.1124410. [PubMed]","DOI":"10.1126\/science.1124410"},{"key":"e_1_3_2_120_2","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rkman J Hughes D Andersson DI. 1998. Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci USA 95:3949\u20133953 http:\/\/dx.doi.org\/10.1073\/pnas.95.7.3949. [PubMed]","DOI":"10.1073\/pnas.95.7.3949"},{"key":"e_1_3_2_121_2","doi-asserted-by":"crossref","unstructured":"Billington OJ McHugh TD Gillespie SH. 1999. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 43:1866\u20131869 http:\/\/dx.doi.org\/10.1128\/AAC.43.8.1866. [PubMed]","DOI":"10.1128\/AAC.43.8.1866"},{"key":"e_1_3_2_122_2","doi-asserted-by":"crossref","unstructured":"Reynolds MG. 2000. Compensatory evolution in rifampin-resistant Escherichia coli. Genetics 156:1471\u20131481.","DOI":"10.1093\/genetics\/156.4.1471"},{"key":"e_1_3_2_123_2","doi-asserted-by":"crossref","unstructured":"Brandis G Wrande M Liljas L Hughes D. 2012. Fitness-compensatory mutations in rifampicin-resistant RNA polymerase. Mol Microbiol 85:142\u2013151 http:\/\/dx.doi.org\/10.1111\/j.1365-2958.2012.08099.x. [PubMed]","DOI":"10.1111\/j.1365-2958.2012.08099.x"},{"key":"e_1_3_2_124_2","doi-asserted-by":"crossref","unstructured":"Heep M Brandst\u00e4tter B Rieger U Lehn N Richter E R\u00fcsch-Gerdes S Niemann S. 2001. Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J Clin Microbiol 39:107\u2013110 http:\/\/dx.doi.org\/10.1128\/JCM.39.1.107-110.2001. [PubMed]","DOI":"10.1128\/JCM.39.1.107-110.2001"},{"key":"e_1_3_2_125_2","doi-asserted-by":"crossref","unstructured":"Taddei F Matic I Radman M. 1995. cAMP-dependent SOS induction and mutagenesis in resting bacterial populations. Proc Natl Acad Sci USA 92:11736\u201311740 http:\/\/dx.doi.org\/10.1073\/pnas.92.25.11736. [PubMed]","DOI":"10.1073\/pnas.92.25.11736"},{"key":"e_1_3_2_126_2","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Verdugo A Gaut BS Tenaillon O. 2013. Evolution of Escherichia coli rifampicin resistance in an antibiotic-free environment during thermal stress. BMC Evol Biol 13:50 http:\/\/dx.doi.org\/10.1186\/1471-2148-13-50. [PubMed]","DOI":"10.1186\/1471-2148-13-50"},{"key":"e_1_3_2_127_2","doi-asserted-by":"crossref","unstructured":"Hughes D Brandis G. 2013. Rifampicin resistance: fitness costs and the significance of compensatory evolution. Antibiotics (Basel) 2:206\u2013216 http:\/\/dx.doi.org\/10.3390\/antibiotics2020206. [PubMed]","DOI":"10.3390\/antibiotics2020206"},{"key":"e_1_3_2_128_2","doi-asserted-by":"crossref","unstructured":"Comas I Borrell S Roetzer A Rose G Malla B Kato-Maeda M Galagan J Niemann S Gagneux S. 2011. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 44:106\u2013110 http:\/\/dx.doi.org\/10.1038\/ng.1038. [PubMed]","DOI":"10.1038\/ng.1038"},{"key":"e_1_3_2_129_2","doi-asserted-by":"crossref","unstructured":"Brandis G Hughes D. 2013. Genetic characterization of compensatory evolution in strains carrying rpoB Ser531Leu the rifampicin resistance mutation most frequently found in clinical isolates. J Antimicrob Chemother 68:2493\u20132497 http:\/\/dx.doi.org\/10.1093\/jac\/dkt224. [PubMed]","DOI":"10.1093\/jac\/dkt224"},{"key":"e_1_3_2_130_2","doi-asserted-by":"crossref","unstructured":"Brandis G Pietsch F Alemayehu R Hughes D. 2015. Comprehensive phenotypic characterization of rifampicin resistance mutations in Salmonella provides insight into the evolution of resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 70:680\u2013685 http:\/\/dx.doi.org\/10.1093\/jac\/dku434. [PubMed]","DOI":"10.1093\/jac\/dku434"},{"key":"e_1_3_2_131_2","doi-asserted-by":"crossref","unstructured":"O\u2019Neill AJ Huovinen T Fishwick CWG Chopra I. 2006. Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence. Antimicrob Agents Chemother 50:298\u2013309 http:\/\/dx.doi.org\/10.1128\/AAC.50.1.298-309.2006. [PubMed]","DOI":"10.1128\/AAC.50.1.298-309.2006"},{"key":"e_1_3_2_132_2","doi-asserted-by":"crossref","unstructured":"de Vos M M\u00fcller B Borrell S Black PA van Helden PD Warren RM Gagneux S Victor TC. 2013. Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob Agents Chemother 57:827\u2013832 http:\/\/dx.doi.org\/10.1128\/AAC.01541-12. [PubMed]","DOI":"10.1128\/AAC.01541-12"}],"container-title":["EcoSal Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/ecosalplus.esp-0017-2019","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/ecosalplus.esp-0017-2019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T23:41:11Z","timestamp":1705534871000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/ecosalplus.esp-0017-2019"}},"subtitle":[],"editor":[{"given":"Susan T.","family":"Lovett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Deborah","family":"Hinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,31]]},"references-count":131,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,31]]}},"alternative-id":["10.1128\/ecosalplus.esp-0017-2019"],"URL":"https:\/\/doi.org\/10.1128\/ecosalplus.esp-0017-2019","relation":{},"ISSN":["2324-6200"],"issn-type":[{"value":"2324-6200","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,31]]},"assertion":[{"value":"2019-11-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"10.1128\/ecosalplus.ESP-0017-2019"}}